Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423070 · ClinicalTrials.gov registry record
Genome Transplant Dynamics
A clinical trial of Thoracic Organ Transplantation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 991
- Enrollment target
- 6
- Study locations
NCT02423070: Recruiting study of Thoracic Organ Transplantation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT02423070 is a study of Thoracic Organ Transplantation that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 991 participants. The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02423070, a study of Thoracic Organ Transplantation, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 991 participants
- Enrollment target
- 6
- Study locations
Study Summary
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early. This study is testing a new, non-invasive blood test that looks for small pieces of DNA from the donor organ in the patient s blood. We believe higher levels of this donor DNA may signal early rejection before damage becomes permanent. Hypothesis: We believe that measuring donor-derived DNA in the blood can help detect early signs of rejection and improve outcomes for transplant patients. The study also collects genetic and biological samples to explore why some people are more at risk of complications after transplant. This may help guide future research and treatments. Who Can Join the Study: People receiving a heart or lung transplant (or both), age 14 and older People who are within three months of their transplant People who can understand and agree to take part in the study Participants will be asked to provide blood and other samples, and some of these will be used in lab research to explore new ideas about how and why transplant rejection happens. This research could lead to better ways to monitor and treat patients after a heart or lung transplant - and help improve long-term survival and quality of life.
Primary Outcome
Fold change in cfDNA at the time of biopsy-proven rejection
Conditions Studied
Study Locations (6)
Maryland
- Johns Hopkins University - Baltimore
- University of Maryland - Baltimore
- National Institutes of Health Clinical Center - Bethesda
Virginia
- INOVA Fairfax Medical - Falls Church
- Virginia Commonwealth University - Richmond
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 991 participants |
| Start Date | 2015-06-25 |
| Est. Completion | 2034-11-30 |
What NCT02423070 shows while recruiting
NCT02423070 is an observational study that tracks outcomes without assigning an intervention. The registered 991 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Thoracic Organ Transplantation appearing as the primary indexed condition, and to 0 interventions.
NCT02423070 lists 6 locations in 3 states (Maryland, Virginia, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02423070 about?
NCT02423070 is a clinical study titled "Genome Transplant Dynamics". Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early. This study is testing a new, non-invasive blood test that looks for small pieces of DNA from the donor organ in the patient s blood. We believe highe...
What is the current status of trial NCT02423070?
This trial is currently recruiting. The enrollment target is 991 participants. The study started on 2015-06-25. Estimated completion is 2034-11-30.
What conditions does trial NCT02423070 study?
This clinical trial studies the following conditions: Thoracic Organ Transplantation.
Who is sponsoring clinical trial NCT02423070?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02423070 being conducted?
This trial has 6 study locations across District of Columbia, Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI